Acknowledgement and Consent for Disclosure of Potential Conflict(s) of Interest and Waiver under 18 U.S.C. § 208(b)(3)

Thomas J.A. Lehman, M.D.

Committee: Arthritis Drugs Advisory Committee

Meeting Date: November 29, 2006

I acknowledge that contingent upon public disclosure of the financial interests listed below, related to new drug application NDA 20-998, supplement 021, trade name, Celebrex (celecoxib), a nonsteroidal anti-inflammatory drug (COX-2 inhibitor), manufactured by Searle Ltd. for G.D. Searle LLC, subsidiaries of Pfizer, for the proposed indication of the relief of the signs and symptoms of juvenile rheumatoid arthritis (JRA) in patients two years and older. I am eligible to receive waivers under 18 U.S.C. §208(b)(3).

Type of Interest	Nature	Magnitude
Speaker Bureau	Competing Less than	n \$10,001 per year
Speaker Bureau	Competing Less than	1 \$10,001 per year

I hereby request that FDA make this information publicly available on my behalf. I understand that without public disclosure of these interests the waivers are not valid.

<u>/S/</u>	October 24, 2006
Signature of SGE	Date